Untitled

There have been many announced situations where it was obviously displayed how average sized pharmaceutical firms indicated better outcomes in developing as a superior undertaking and hence performing with much better and effective outcomes in the up and coming future. There have been numerous models that have additionally celebrated the way that these pharmaceutical firms have been exceptionally overseen and run, which have proved to be very productive for the proprietors and the ones that are associated with them in whichever way. Ajit Kamath Arch Pharmalab is one such splendid model. Spread across 8 assembling areas, taking into account worldwide clients Arch has been effectively assessed by the USFDA-EDQM-PMDA-KFDA-TGA and other administrative bodies. Curve centers around Biocatalysis , Diazomethane science, Fermentation, Organometallic science and so forth. 

Take the instance of three youthful companions, Ajit Kamath, Manoj Jain and Rajendra Kaimal, who chose to wander into pharmaceutical business 10 years prior. Presently, they own 11 medication producing units, two innovative work units and utilize more than 2,500 individuals in their Arch Pharmalabs. With a turnover of over Rs 1,200 crore, it is one of the biggest Indian agreement producing players for worldwide pharma. There are a few such medium size pharma organizations, numerous unlisted, outpacing the industry growth. Fundamentally centered around Generics, Arch has been at the cutting edge of pathbreaking forms for Atorvastatin, Urso Deoxycholid Acid (UDCA) , Advanced Intermediates for different ARVs and numerous different items. Curve is open for unions with accomplices in the CDMO/CRAMS space. 

They aren't commonly recognised names; however the feisty cultivators might be tomorrow's development story. Originating from a non-pharma foundation and specialization in money related administrations, they began business by being a little wiped out unit in Hyderabad, in the starting times. Sponsored by investment subsidizing, they affected nine little acquisitions in various pieces of the nation inside 10 years and improved assembling limits and quality principles of obtained units. Through every one of these accomplishments they safe house demonstrated their value as well as have given numerous business chances to the general public which thusly helpsour nation in unfathomable manners. 

Arch Pharmalabs is a popular mention in the Pharmaceutical arena. All thanx to the visionary insights of Ajit Kamath Arch Pharmalabs has seen astounding success. Starting with a financial services company, the group got metamorphosed into a leading active pharmaceutical intermediates (API) manufacturing corporation in some rather curious twist and turn of fate. Broadly it is based in Mumbai and its suburbs as well as in seven other locations throughout India, the firm has been in the field for more than two decades. 

The group came into the pharma foray with the acquisition of an ailing enterprise Merven Pharmaceuticals. Business model and the economic viability of the Merven enterprise were thoroughly sound and this aspect brought his abilities towards it, recalls Kamath. Saddled with debt, Merven filed for a reconstruction program. It was then, Mr. Kamath along with other co-partners acquired the firm by pooling the resource and named it Arch Pharma Labs. Undergoing through a process of massive reconstruction under its visionary architect, the firm became net positive within the first three years.

Initially, the group was involved in selling intermediates for penicillin in the overseas market. The firm had a healthy mix of domestic as well as overseas presence. The lucrative nature of Mumbai along with the availability of large unsaturated domestic markets led the firm to step up the production line and pressure the growth pedal. Since then the group has been engaged in making active ingredients for several diseases such as cardiovascular, diabetes, and malaria.

The company's business profile is bifurcated across two verticals i.e. products and services. The product segment is engaged in the manufacture and selling of API as well as intermediaries to other pharma companies. The notable list of clients includes Cipla, Ranbaxy, Sandoz to name a few. On the service side, the firm engages in strategic collaboration and alliances along with marketing agreements. The company has evolved state of art research laboratories to cater to CRAMS (Contract Research and Manufacturing Services) from its inception to destination. 

 It has gained funding from renowned institutional investors such as ICICI ventures, Swiss Tec and NBFC major IL&FS. However, the director groups hold the majority stakes in the firm i.e. around 58% of the Arch Pharmalabs equity. Under the supervision of Ajit Kamath Arch Pharmalabs has been involved in forming great tie-ups with pharma giants such as Codexis, Orochem (US), DSM (Netherlands) along with several of the vendor pharma companies of repute. Through these businesses and collaborations are hopeful for bringing some extremely critical developments in the pharma sector to the domestic pharmaceutical division says Mr. Kamath.

The company has diversified its portfolio swiftly and has been engaged in making more than hundred of pharmaceutical products ranging from products catering to therapeutic segments, NSAIDs, Lipid-Lowering Agents, Anti-Anginal segments, Anti-Retroviral, Oncology, Anti-Asthmatic, etc. The firm has also extended its service ceilings under CRAMS from just contract research to safety studies, route selection, analytical development, clinical trial manufacture, and stability studies. The group has established 8 centers of excellence equipped with reactor capacities amounting to around 1200 KL across India. 

Huge domestic demands coupled with the increasing overseas request has made the company undergo an acquisition spree by acquiring six ingredients manufacturing companies and several vendor companies along with its production line. Its Medak unit has cGMP, ISO 9001, ISO 14001, OHSAS 18001:2007 certification along with USFDA accreditation. The same can be said about its Gurgaon unit which boasts of all the above-mentioned certifications and WHO, EU, EMA, and KFDA accreditation. The last of the unit at Dombivli, Mumbai is equipped with cGMP certifications and ISO 14001 benchmark standards.

Arch pharmalabs are the leading manufacturer in the pharmacy industry. They are offering a product mix of more than 120 products across various therapeutic segments. The range of services is extending their business under CRAMS starting from route selection to commercial manufacture. The company quality policies ensure compliance with current guidelines and providing adequate resources to management in achievement thereof.

Manoj Jain, Deputy Managing Director is responsible for planning and formulating the overall business strategy of the company. He has taken overall – in charge of the accounting and finance functions of Arch pharmalabs directors. He is committed to the corporate policy, strategic and perspective planning and external relations for the company.

In a competitive edge, the company has aligned across two business verticals viz. products and services. The company has developed quality and efficiency in the delivery of products and services through the latest R&D and technology. With a scale of operations ranging from multi-product facilities, the company has capabilities to handle several complexities in a cost-effective manner. The director of Arch pharmalabs has benefited from an agreement with leading technology providers based in the US, UK, and Europe. The company is implementing various green chemistry initiatives which help in reducing production costs and improving the quality of the products.

Manoj Jain is responsible to identify and update systems for the safety, health & environmental hazards and risk associated with products. The company has incorporated with effluent treatment plants to set environmental health and safety objectives. Achieving total customer satisfaction, improving quality management systems and full compliance with all applicable statutory and regulatory requirements is the priority.

After expanding product range and changing in product mix, helps in increasing the demand of the customers. The company serves customer requirements ranging from laboratory scale research to commercial production. To promote recycling and green chemistry, they have established a solvent recycling plant which reduces harmful emissions. Arch pharmalabs manufacturing facilities are designed to manufacture a variety of API and intermediaries using a combination of the process.

No doubts, the firm is a generic pharmaceutical player in both domestic and international market. The company believes in establishing and pursuing quality objectives and performance standards. With educated and trained employees, the management has a primary responsibility for improving conditions in order to prevent accidents, health hazards, and pollution. The company categorize high-risk areas and improve conditions for enhancing safety.